Our Partners

AVEO is committed to discovering, developing and commercializing targeted cancer therapies to impact patients’ lives. To support these efforts, we continue to evaluate opportunities to collaborate with other pharmaceutical and biotechnology companies that share AVEO’s vision for oncology drug development. Importantly, as AVEO continues to build its commercial infrastructure, we seek collaborations that align with our strategic, long-term corporate goals.

AVEO has entered into multiple types of strategic partnership arrangements with several leading pharmaceutical and biotech companies:

  • In-licensing of targeted clinical stage compounds

    In December 2006, AVEO entered into a license agreement with Kirin Brewery Co. Ltd. (now Kyowa Hakko Kirin) under which we obtained an exclusive license to research, develop, manufacture and commercialize tivozanib (f/k/a KRN951), pharmaceutical compositions thereof and associated biomarkers. AVEO’s exclusive license covers all territories in the world, except for Asia.

  • Funded research collaboration utilizing AVEO's proprietary technology platform

    In December 2010, AVEO and OSI Pharmaceuticals, Inc. (which is a wholly owned subsidiary of Astellas U.S. Holding Inc., a holding company owned by Astellas Pharma Inc.) announced that OSI exercised its option under the parties’ July 2009 agreement providing the right for OSI to internalize certain elements of AVEO’s proprietary technology platform, including components of the Human Response Platform™ for the identification/characterization of novel epithelial-mesenchymal transition (EMT) agents and proprietary patient selection biomarkers, in support of OSI’s clinical development programs. The July 2009 agreement was an expansion of the drug discovery and translational research collaboration announced in October 2007. The alliance between AVEO and OSI was anchored around developing molecularly targeted therapies to target the underlying mechanisms of EMT in cancer and to develop patient selection biomarkers to support OSI’s targeted medicine pipeline. EMT is a process of emerging significance in tumor growth and disease progression and a focal point of discovery and translational research in oncology drug development. The companies expanded their efforts in 2009 to validate cancer targets and to deploy key elements of AVEO’s Human Response Platform in support of OSI’s ongoing clinical development programs. The collaborative research portion of the arrangement ended in July 2011.

  • Exclusive, Worldwide In-Licensing of GDF-15 Patents for Certain Symptoms of Cachexia

    In June 2012, AVEO entered into a license agreement with St. Vincent’s Hospital Sydney under which AVEO obtained an exclusive, worldwide license to research, develop, manufacture and commercialize products for therapeutics applications that benefit from inhibition or decreased expression or activity of GDF-15. AVEO is using this license for its AV-380 program in cachexia.

  • If you would like more information on current partnering opportunities with AVEO, we invite you to read more about our specific areas of interest or contact aveobd@aveooncology.com.